Dr. Yang Naibo received his Ph.D. in Physiology from Thomas Jefferson University in 1995 (under the tutelage of Professor Richard Horn, a famous neurophysiologist). He has more than 10 years of multidisciplinary and cross-technology platform R&D and management experience in biology, medicine, diagnosis, and new drug research and development. He has served as senior researcher, project leader, and senior manager in American companies Exelixis, Affymax, and Molecular Devices. His expertise is mainly in the fields of oncology, immunity, neurophysiology, etc.; he entered the company's senior management in 2008 and served as the vice president of Biochain and the vice president of Baitai Pharmaceutical; he started his business in 2011 and founded United Bioresearch Inc. in Silicon Valley, USA. Dr. Yang has experience in the development of biomedical instruments and reagents, and has successfully developed a number of 510(K) diagnostic reagent products certified by the US FDA. The mainstream products include tumor marker detection, hormone detection, infectious disease detection and other diagnostic reagents box.
      In 2017, Dr. Yang Naibo was hired as the deputy general manager of BioPredia BioTech Co., Ltd responsible for the development of autoimmune products, and was selected into the fifth batch of "113 Special Medical Talents Program" of China Medical City.